Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Entrada Therapeutics, Inc. (TRDA : NSDQ)
 
 • Company Description   
Entrada Therapeutics Inc. is a biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicles(TM) to engage intracellular targets. Entrada Therapeutics Inc. is based in BOSTON.

Number of Employees: 78

 
 • Price / Volume Information   
Yesterday's Closing Price: $26.73 Daily Weekly Monthly
20 Day Moving Average: 174,804 shares
Shares Outstanding: 29.89 (millions)
Market Capitalization: $798.88 (millions)
Beta:
52 Week High: $36.85
52 Week Low: $20.00
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 7.44% 10.79%
12 Week % %
Year To Date % %
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
6 TIDE STREET
-
BOSTON,MA 02210
USA
ph: 857-520-9158
fax: -
investors@entradatx.com http://www.entradatx.com
 
 • General Corporate Information   
Officers
Dipal Doshi - Chief Executive Officer and President
Kush M. Parmar - Chairman
Nathan J. Dowden - Chief Operating Officer
Kory Wentworth - Chief Financial Officer
John F. Crowley - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 29384C108
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: -
Next Expected EPS Date: -
Share - Related Items
Shares Outstanding: 29.89
Most Recent Split Date: (:1)
Beta:
Market Capitalization: $798.88 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: -  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
09/30/21 - -
06/30/21 - -
03/31/21 - -
ROA
09/30/21 - -
06/30/21 - -
03/31/21 - -
Current Ratio
09/30/21 - -
06/30/21 - -
03/31/21 - -
Quick Ratio
09/30/21 - -
06/30/21 - -
03/31/21 - -
Operating Margin
09/30/21 - -
06/30/21 - -
03/31/21 - -
Net Margin
09/30/21 - -
06/30/21 - -
03/31/21 - -
Pre-Tax Margin
09/30/21 - -
06/30/21 - -
03/31/21 - -
Book Value
09/30/21 - -
06/30/21 - -
03/31/21 - -
Inventory Turnover
09/30/21 - -
06/30/21 - -
03/31/21 - -
Debt-to-Equity
09/30/21 - -
06/30/21 - -
03/31/21 - -
Debt-to-Capital
09/30/21 - -
06/30/21 - -
03/31/21 - -
 

Powered by Zacks Investment Research ©